Correction: SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells

Yang Yang, Xiaokun Gu, Weiji Weng, Jinke Cheng, Ou Huang, Si-Jian Pan, Yong LiCell 2024 · DOI · OpenAlex

Introduction

The pursuit of scientific knowledge relies heavily on the accuracy and transparency of published data. This document provides a formal correction to the research article "SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells," which appeared in the journal Cell Communication and Signaling. The correction is necessary to rectify a clerical error in the supplementary materials that occurred during the final stages of manuscript preparation.

The Biological Significance of TRPV1 in Gastric Cancer

To understand the importance of this correction, it is helpful to revisit the core findings of the original research. Gastric cancer remains a highly aggressive malignancy, necessitating the discovery of new molecular targets for treatment. The authors focused on TRPV1 (Transient Receptor Potential Vanilloid 1), a non-selective cation channel. While widely known for its role in heat and pain sensation, recent studies have highlighted its involvement in cell signaling pathways related to cancer.

The original study identified a specific regulatory mechanism: SUMOylation. This is a post-translational modification where a Small Ubiquitin-like Modifier (SUMO) protein is covalently attached to a target protein—in this case, TRPV1. The researchers discovered that this modification acts as a "postal code" for the cell, dictating the physical location of TRPV1. Specifically, SUMOylation induces the localization of TRPV1 to the cell membrane.

The "aha moment" of the research was the discovery that the function of TRPV1 is dependent on its location. When localized to the membrane, TRPV1 serves as a tumor suppressor. It inhibits proliferation (the rapid division of cancer cells) and migration (the ability of cancer cells to move and invade other tissues). This suggests that the SUMOylation pathway could be a viable therapeutic target; by promoting the membrane localization of TRPV1, clinicians might be able to suppress the aggressive characteristics of gastric tumors.

Details of the Correction: Transposed Supplementary Figures

The correction notice specifically addresses the transposition of Figure S2 and Figure S5 within the supplementary materials. During the assembly of Supplementary File 1, these two figures were accidentally swapped.

In scientific publishing, supplementary figures often provide essential context, such as:

  • Validation Assays: Confirming the SUMOylation of TRPV1 using biochemical methods.
  • Localization Data: Tracking the movement of the protein using immunofluorescence or cellular fractionation.
  • Functional Assays: Measuring the impact on cell growth and movement across different gastric cancer cell lines.

The authors have now provided the corrected files, ensuring that Figure S2 and Figure S5 are in their proper locations. They have confirmed that this clerical error does not change the interpretation of the data or the validity of the study's conclusions. The core message—that membrane-bound TRPV1 suppresses gastric cancer—remains robust.

Methods and Data Integrity

While this notice does not detail new experimental methods, it highlights the importance of internal audits and the "Check for updates" mechanism in modern publishing. The original study likely employed a suite of molecular biology techniques, including cell culture models of gastric cancer, biochemical assays to detect protein modifications, and functional assays to observe cell behavior.

The correction process demonstrates the authors' commitment to data integrity. Even in supplementary materials, which are sometimes viewed as secondary to the main text, accuracy is paramount for peer replication. The restoration of these figures ensures that the scientific community has a clear and accurate roadmap of the authors' experimental journey.

Future Directions

The correction allows the scientific community to move forward with a clear record. Future research in this area will likely transition from in vitro cell culture models to in vivo studies, such as animal models, to determine if the TRPV1 SUMOylation mechanism operates similarly in the complex environment of a living organism. Additionally, researchers may look for pharmacological agents that can enhance the SUMOylation of TRPV1, potentially leading to new treatments for patients with gastric cancer.

Conclusion

This correction notice serves to maintain the high standards of the journal Cell Communication and Signaling and the credibility of the research team. By ensuring that Figure S2 and Figure S5 are correctly placed, the authors have preserved the integrity of a study that offers significant insights into the molecular regulation of gastric cancer.

Summary updated

BibTeX
@inproceedings{yang2024correction,
  author = {Yang Yang and Xiaokun Gu and Weiji Weng and Jinke Cheng and Ou Huang and Si-Jian Pan and Yong Li},
  title = {{Correction: SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells}},
  booktitle = {Cell},
  year = {2024},
  doi = {10.1186/s12964-024-01864-8},
}
Figure